Association of vitamins, minerals, and lead with lipoprotein(a) in a cross-sectional cohort of US adults
Abstract
Abstract: Lipoprotein(a)(Lp[a]) is a low-density lipoprotein-cholesterol (LDL-C)-like particle with potent pro-atherothrombotic properties. The association of Lp(a) with several circulating factors, including vitamins, remains unresolved. We performed an observational analysis using the National Health and Nutrition Examination Survey III cohort, a cohort used to monitor the nutrition status of US-citizens. We used multivariable linear regression to test associations of Lp(a) and LDL-C with levels of serum vitamins and minerals and whole-blood lead. Analyses controlled for factors known to associate with Lp(a) (age, sex, race/ethnicity, statin use, hemoglobin A1c, body mass index, hypertension, diabetes, glomerular filtration rate, alcohol intake, and saturated fat intake). LDL-C was corrected for Lp(a) mass. Multiple sensitivity tests were performed, including considering factors as categorical variables (deficient, normal, elevated). Among 7,662 subjects, Lp(a) correlated (β-coefficient) positively (change per 1 conventional unit increase) with carotenoids (lycopene (0.17(0.06,0.28), p=0.005), lutein (0.19(0.07,0.30), p=0.002), β-cryptoxanthin (0.21(0.05,0.37), p=0.01), β-carotene (0.05(0.02,0.09), p=0.003), and α-carotene (0.15(0.01,0.30), p=0.04)) and lead (0.54(0.03,1.05), p=0.04) levels when tested as continuous variables. LDL-C had similar associations. Lp(a) did not associate with vitamins A, B12, C, or E retinyl esters, folate, RBC-folate, selenium, ferritin, transferrin saturation, or calcium. With factors as categorical variables, Lp(a) but not LDL-C negatively associated with elevated vitamin B12 (−5.41(−9.50, −1.53), p=0.01) and folate (−2.86(−5.09, −0.63), p=0.01). In conclusion, Lp(a) associated similarly to LDL-C when vitamins, minerals, and lead were tested as continuous variables, while only Lp(a) correlated with vitamin B12 and folate when tested as categorical variables. These observations are hypotheses generating and require further studies to determine causality.
References
1 . A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69(6):692–711.
2 Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844–53.
3 . Lipoprotein(a) levels and association with myocardial infarction and stroke in a nationally representative cross-sectional US cohort. J Clin Lipidol. 2020;14(5):695–706.e4.
4 . 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019.
5 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018.
6 . Dietary and genetic interactions in the regulation of plasma lipoprotein(a). Curr Opin Lipidol. 1999;10(1):35–40.
7 . Lipoprotein (a): impact by ethnicity and environmental and medical conditions. J Lipid Res. 2016;57(7):1111–25.
8 . Lipoprotein (a): More than a bystander in the etiology of hypertension? A study on essential hypertensive patients not yet on treatment. J Nephropathol. 2013;2(1):67–70.
9 Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2012;125(2):241–9.
10 . N-acetylcysteine and lipoprotein(a). Lancet. 1992;339(8785):126–7.
11 . Dose-related increase of HDL-cholesterol levels after N-acetylcysteine in man. Pharmacol Res. 1993;28(3):213–8.
12 . Lipoprotein(a) reduction by N-acetylcysteine. Lancet. 1991;337(8735):203–4.
13 . N-acetylcysteine and serum concentrations of lipoprotein(a). J Intern Med. 1991;230(6):519–26.
14 . Future directions to establish lipoprotein(a) as a treatment for atherosclerotic cardiovascular disease. Cardiovasc Drugs Ther. 2016;30(1):101–8.
15 . Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). Br J Sports Med. 2004;38(3):253–9.
16 Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2016;6:19188.
17 Curcuminoids modify lipid profile in type 2 diabetes mellitus: A randomized controlled trial. Complement Ther Med. 2017;33:1–5.
18 . Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: A systematic review and meta-analysis. Pharmacol Res. 2016;105:198–209.
19 L-carnitine/simvastatin reduces lipoprotein (a) levels compared with simvastatin monotherapy: a randomized double-blind placebo-controlled study. Lipids. 2017;52(1):1–9.
20 The effects of omega-3 fatty acids and vitamin E co-supplementation on gene expression of lipoprotein(a) and oxidized low-density lipoprotein, lipid profiles and biomarkers of oxidative stress in patients with polycystic ovary syndrome. Mol Cell Endocrinol. 2017;439:247–55.
21 Vitamin C down-regulate apo(a) expression via Tet2-dependent DNA demethylation in HepG2 cells. Int J Biol Macromol. 2017;98:637–45.
22 Plasma lipoprotein (a) levels in men and women consuming diets enriched in saturated, cis-, or trans-monounsaturated fatty acids. Arterioscler Thromb Vasc Biol. 1997;17(9):1657–61.
23 . Postprandial lipoprotein(a) is affected differently by specific individual dietary fatty acids in healthy young men. J Nutr. 2004;134(10):2550–5.
24 . Serum lipoprotein(a) concentrations and alcohol consumption in hypertension: possible relevance for cardiovascular damage. J Hypertens. 2003;21(2):281–8.
25 Social alcohol consumption and low Lp(a) lipoprotein concentrations in middle aged Finnish men: population based study. BMJ. 1998;316(7131):594–5.
26 . Does coffee consumption alter plasma lipoprotein(a) concentrations? A systematic review. Crit Rev Food Sci Nutr. 2018;58(10):1706–14.
27 . Lipoprotein(a): current evidence for a physiologic role and the effects of nutraceutical strategies. Clin Ther. 2019;41(9):1780–97.
28 Plan and operation of the Third National Health and Nutrition Examination Survey, 1988–94. Series 1: programs and collection procedures. Vital Health Stat 1. 1994;32:1–407.
29 . Laboratory procedures used for the Third National Health and Nutrition Examination Survey (NHANES III), 1988–1994. U.S. Department of Health and Human Services; 1996.
30 Comparison of a novel method vs the friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA. 2013;310(19):2061–8.
31 Lipoprotein(a) reduction in persons with cardiovascular disease. NEJM. 2020;382(3):244–55.
32 . Recommended Actions Based on Blood Lead Level cdc.gov2020 [updated Nov 2, 2020; cited 2020 Nov 13]. Available from: https://www.cdc.gov/nceh/lead/advisory/acclpp/actions-blls.htm
33 , Therapeutic lipidology. contemporary cardiology. In M DavidsonP TothKC Maki, editors. Humana Press; 2021. p. 489.
34 . Prevalence of elevated Lp(a) mass levels and patient thresholds in 532359 patients in the united states. Arterioscler Thromb Vasc Biol. 2016;36(11):2239–45.
35 Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the Multi-Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol. 2015;35(4):996–1001.
36 . Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans. J Lipid Res. 1996;37(12):2569–85.
37 Lipoprotein(a) Concentrations in Mexican Americans and Non-Hispanic Whites: The San Antonio Heart Study. Am J Epidemiol. 1992;136(9):1060–8.
38 . Change in plasma lutein after egg consumption is positively associated with plasma cholesterol and lipoprotein size but negatively correlated with body size in postmenopausal women. J Nutr. 2007;137(4):959–63.
39 . Correlates of the difference in plasma carotenoid concentrations between men and women. Br J Nutr. 2019;121(2):172–81.
40 Non-dietary correlates and determinants of plasma lutein and zeaxanthin concentrations in the Irish population. J Nutr Health Aging. 2017;21(3):254–61.
41 . Low-level exposure to lead as a cardiovascular risk factor. In: , editor. Cardiovasc risk factor. InTech. 2012.
42 . Absorption, metabolism, and transport of carotenoids. FASEB J. 1996;10(5):542–51.
43 . No effect of β-carotene supplementation on plasma lipoproteins in healthy smokers. Am J Clin Nutr. 1994;60(5):730–4.
44 . Oxidative modification of lipoprotein(a) and the effect of beta-carotene. Metabolis. 1992;41(11):1215–24.
45 . Dietary carotenoids and risk of coronary artery disease in women. Am J Clin Nutr. 2003;77(6):1390–9.
46 . Antioxidant properties of carotenoids in vitro and in vivo. Food Rev Int. 2004;20(2):99–121.
47 . Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet. 2003;361(9374):2017–23.
48 . Carotenoids and cardiovascular health. Am J Clin Nutr. 2006;83(6):1265–71.
49 . Homocysteine, fibrinogen, and lipoprotein(a) levels are simultaneously reduced in patients with chronic renal failure treated with folic acid, pyridoxine, and cyanocobalamin. Metabolis. 2001;50(2):131–4.
50 Effects of lead and mercury on the blood proteome of children. J Proteome Res. 2010;9(9):4443–53.
51 . Lipoprotein(a) mass levels increase significantly according to apoe genotype: an analysis of 431 239 patients. Arterioscler Thromb Vasc Biol. 2017;37(3):580–8.
52 Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol. 2013;62(17):1575–9.
53 . Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans. J Lipid Res. 2016;57(3):340–51.
54 Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet. 2016;388(10057):2239–53.
